Helpdesk

Sales contact

Home > Resources > Insights from Kayentis clients: why you should choose Kayentis as your eCOA & DCT provider

Insights from Kayentis clients: why you should choose Kayentis as your eCOA & DCT provider

Last updated: July 3, 2024

Responsiveness, reliability, professionalism, friendliness… discover why 95.6% of Kayentis clients recommend Kayentis in 2023!

Challenge your eCOA & DCT provider: choose Kayentis for your next clinical trial!

Subscribe to our newsletter

ePRO in early phase oncology trials: A revolution on the...

Patient-Reported Outcomes in early-phase oncology clinical trialsA Stepping Stone to...

Answering the Sustainability Call: Digital Health Technologies and eCOA

Kayentis secures Silver Medal in EcoVadis sustainability evaluation with significant...

Engage patients throughout the clinical trial journey

Rethinking Phase 1 Oncology Trials with Electronic Patient-Reported Outcomes

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events